Blocking Interleukin-1β transiently limits left ventricular dilation and reduces cardiac lymphangiogenesis in a mouse pressure-overload model
C. Heron,T. Lemarcis,M. Bundalo,O. Laguerre,C Valentin,M. Valet,JB Michel,P. Mulder,A. Zernecke,V. Tardif,E. Brakenhielm
DOI: https://doi.org/10.1101/2023.04.01.535056
2024-02-21
Abstract:Blocking inflammatory pathways, e.g. the inflammasome or interleukin (IL)-1β, is a promising therapeutic approach in heart failure (HF). We hypothesized that IL-1β may stimulate cardiac lymphangiogenesis in response to left ventricular (LV) dilation following pressure-overload. Consequently, blocking IL-1β may reduce lymphangiogenesis, delaying resolution of myocardial edema and inflammation, aggravating cardiac fibrosis, and accelerating HF development. Here we investigated the effects of anti-IL-1β treatment during HF development following pressure-overload, induced by transaortic constriction (TAC) in BALB/c mice prone to LV dilation. We examined the molecular mechanisms of IL-1β in macrophages and lymphatic endothelial cells, and assessed links between perivascular fibrosis and lymphatics in HF patients with ischemic or dilated cardiomyopathy (DCM). We found that early anti-IL-1β treatment transiently delayed LV dilation, but did not alter cardiac lymphangiogenesis, hypertrophy, or dysfunction at 8 weeks post-TAC. In contrast, late anti-IL-1β treatment reduced cardiac lymphangiogenesis in response to LV dilation. This was linked to a cell non-autonomous role of IL-1β in promoting cardiac lymphangiogenesis through stimulation of macrophage production and maturation of VEGF-C. Surprisingly, despite reduced lymphatic density in late anti-IL-1β-treated mice, cardiac inflammation, interstitial fibrosis, and dysfunction were not aggravated. Further, we found that perivascular lymphatic density, unaltered by IL-1β, was negatively associated with perivascular fibrosis in HF patients and our TAC model. In conclusion, IL-1β blockage elicited transient functional cardiac benefit when initiated before onset of LV dilation post-TAC in mice. In contrast, late treatment reduced cardiac lymphangiogenesis, but did not significantly accelerate HF development, likely reflecting lymphatic transport dysfunction post-TAC. Our data suggest that the therapeutic window for anti-IL-1β treatment is crucial, as initiation of treatment during the lymphangiogenic response, induced by LV dilation, may diminish the potential cardiac benefit in HF patients. Finally, our data indicate that IL-1β-independent perivascular lymphangiogenesis may limit perivascular fibrosis.
Physiology